Amrita University in southern India has developed what it bills as a low-cost insulin pump about one-tenth as expensive as imported alternatives. The university is also apparently talking to two "biomedical devices" companies about producing it commercially, though the school hasn't disclosed any names, according to The Hindu Business Line. Larger insulin pump makers like Medtronic ($MDT) may want to take note. With India's emerging market of 1 billion-plus people, we've long known that there are enormous opportunities there for life sciences companies, and either one of the parties in negotiations could be a major player. But the article also emphases the goal of developing a product that is much cheaper than "imported pumps," and a local enterprise based in India could easily win out in producing the cell-phone sized insulin delivery system. Story